| related words |
| neuropathic |
| preapproval |
| ipilimumab |
| synthesis |
| finishing |
| analyzer |
| medimmune |
| carcinogenicity |
| abthrax |
| decodeme |
| arcalyst |
| enzyme |
| norcross |
| ppi |
| expression |
| apio |
| carlsbad |
| unpartnered |
| manufacturable |
| kaketsuken |
|
| related documents |
| 1333248--3/28/2007--CADENCE_PHARMACEUTICALS_INC |
|
| related topics |
| {product, candidate, development} |
| {loss, insurance, financial} |
| {customer, product, revenue} |
| {capital, credit, financial} |
| {cost, regulation, environmental} |
| {provision, law, control} |
| {operation, international, foreign} |
| {cost, contract, operation} |
| {system, service, information} |
| {loan, real, estate} |
| {acquisition, growth, future} |
| {stock, price, operating} |
| {personnel, key, retain} |
| {condition, economic, financial} |
| {debt, indebtedness, cash} |
| {tax, income, asset} |
| {cost, operation, labor} |
| {competitive, industry, competition} |
| {financial, litigation, operation} |
| {control, financial, internal} |
|